Quantisnow Logo
Dashboard

SEC Form SC 13G/A filed by Pacira BioSciences Inc. (Amendment)

$PCRX
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $PCRX alert in real time by email
SC 13G/A 1 d212954dsc13ga.htm SC 13G/A SC 13G/A

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No. 3)*

 

 

Pacira Biosciences Inc.

(Name of Issuer)

Common Shares

(Title of Class of Securities)

695127100

(CUSIP Number)

December 31, 2021

(Date of Event Which Requires Filing of this Statement)

 

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☒ Rule 13d-1(b)

☐ Rule 13d-1(c)

☐ Rule 13d-1(d)

 

*

The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

 

Page 1 of 14

CUSIP No. 695127100  

 

 

  1.   

Names of Reporting Persons

 

Macquarie Group Limited

  2.  

Check the Appropriate Box if a Member of a Group (See Instructions)

(a)  ☒        (b)  ☐

 

  3.  

SEC Use Only

 

    

  4.  

Citizenship or Place of Organization

 

Sydney, New South Wales Australia

Number of

Shares

Beneficially

Owned by

Each

Reporting

Person

With

    5.    

Sole Voting Power

 

0

   6.   

Shared Voting Power

 

0

   7.   

Sole Dispositive Power

 

0

   8.   

Shared Dispositive Power

 

0

  9.  

Aggregate Amount Beneficially Owned by Each Reporting Person

 

4,205,522 deemed beneficially owned due to reporting person’s ownership of Macquarie Management Holdings Inc., Macquarie Investment Management Business Trust, Ivy Investment Management Company and Macquarie Investment Management Global Limited whose individual holdings are shown on the following forms.

10.  

Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  ☐

 

    

11.  

Percent of Class Represented by Amount in Row (9)

 

9.44%

12.  

Type of Reporting Person (See Instructions)

 

HC

 

 

Page 2 of 14

CUSIP No. 695127100  

 

 

  1.   

Names of Reporting Persons

 

Macquarie Management Holdings Inc

  2.  

Check the Appropriate Box if a Member of a Group (See Instructions)

(a)  ☒        (b)  ☐

 

  3.  

SEC Use Only

 

    

  4.  

Citizenship or Place of Organization

 

State of Delaware

Number of

Shares

Beneficially

Owned by

Each

Reporting

Person

With

    5.    

Sole Voting Power

 

3,747,440

   6.   

Shared Voting Power

 

0

   7.   

Sole Dispositive Power

 

3,747,440

   8.   

Shared Dispositive Power

 

0

  9.  

Aggregate Amount Beneficially Owned by Each Reporting Person

 

3,747,440 deemed beneficially owned due to reporting person’s ownership of Macquarie Investment Management Business Trust

10.  

Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  ☒

 

    

11.  

Percent of Class Represented by Amount in Row (9)

 

8.41%

12.  

Type of Reporting Person (See Instructions)

 

HC

 

 

Page 3 of 14

CUSIP No. 695127100  

 

 

  1.   

Names of Reporting Persons

 

Macquarie Investment Management Business Trust

  2.  

Check the Appropriate Box if a Member of a Group (See Instructions)

(a)  ☒        (b)  ☐

 

  3.  

SEC Use Only

 

    

  4.  

Citizenship or Place of Organization

 

State of Delaware

Number of

Shares

Beneficially

Owned by

Each

Reporting

Person

With

    5.    

Sole Voting Power

 

3,747,440

   6.   

Shared Voting Power

 

0

   7.   

Sole Dispositive Power

 

3,747,440

   8.   

Shared Dispositive Power

 

0

  9.  

Aggregate Amount Beneficially Owned by Each Reporting Person

 

3,747,440

10.  

Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  ☒

 

    

11.  

Percent of Class Represented by Amount in Row (9)

 

8.41%

12.  

Type of Reporting Person (See Instructions)

 

IA

 

 

Page 4 of 14

CUSIP No. 695127100  

 

 

  1.   

Names of Reporting Persons

 

Macquarie Investment Management Group Limited

  2.  

Check the Appropriate Box if a Member of a Group (See Instructions)

(a)  ☒        (b)  ☐

 

  3.  

SEC Use Only

 

    

  4.  

Citizenship or Place of Organization

 

Sydney, New South Wales, Australia

Number of

Shares

Beneficially

Owned by

Each

Reporting

Person

With

    5.    

Sole Voting Power

 

1,075

   6.   

Shared Voting Power

 

0

   7.   

Sole Dispositive Power

 

1,075

   8.   

Shared Dispositive Power

 

0

  9.  

Aggregate Amount Beneficially Owned by Each Reporting Person

 

1,075

10.  

Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  ☐

 

    

11.  

Percent of Class Represented by Amount in Row (9)

 

0.00%

12.  

Type of Reporting Person (See Instructions)

 

CO

 

 

Page 5 of 14

CUSIP No. 695127100  

 

 

  1.   

Names of Reporting Persons

 

Delaware Smid Cap Growth Fund, a series of Delaware Group Equity Funds IV

  2.  

Check the Appropriate Box if a Member of a Group (See Instructions)

(a)  ☒        (b)  ☐

 

  3.  

SEC Use Only

 

    

  4.  

Citizenship or Place of Organization

 

State of Delaware

Number of

Shares

Beneficially

Owned by

Each

Reporting

Person

With

    5.    

Sole Voting Power

 

3,073,213

   6.   

Shared Voting Power

 

0

   7.   

Sole Dispositive Power

 

3,073,213

   8.   

Shared Dispositive Power

 

0

  9.  

Aggregate Amount Beneficially Owned by Each Reporting Person

 

3,073,213

10.  

Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  ☐

 

    

11.  

Percent of Class Represented by Amount in Row (9)

 

6.90%

12.  

Type of Reporting Person (See Instructions)

 

IC

 

 

Page 6 of 14

CUSIP No. 695127100  

 

 

  1.   

Names of Reporting Persons

 

Ivy Investment Management Company

  2.  

Check the Appropriate Box if a Member of a Group (See Instructions)

(a)  ☒        (b)  ☐

 

  3.  

SEC Use Only

 

    

  4.  

Citizenship or Place of Organization

 

State of Delaware

Number of

Shares

Beneficially

Owned by

Each

Reporting

Person

With

    5.    

Sole Voting Power

 

457,007

   6.   

Shared Voting Power

 

0

   7.   

Sole Dispositive Power

 

457,007

   8.   

Shared Dispositive Power

 

0

  9.  

Aggregate Amount Beneficially Owned by Each Reporting Person

 

457,007

10.  

Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  ☐

 

    

11.  

Percent of Class Represented by Amount in Row (9)

 

1.03%

12.  

Type of Reporting Person (See Instructions)

 

IA

 

 

Page 7 of 14

Item 1.

 

  (a)

Name of Issuer

Pacira Pharmaceuticals Inc.

 

  (b)

Address of Issuer’s Principal Executive Offices

5 Sylvan Way Ste 300, Parsippany, NJ 07054

 

Item 2.

 

  (a)

Name of Person Filing

This Schedule 13G is jointly filed by Macquarie Group Limited, Ivy Investment Management Company Macquarie Management Holdings Inc, Macquarie Investment Management Business Trust, Macquarie Investment Management Global Limited

 

  (b)

Address of Principal Business Office or, if none, Residence

The principal business address of Macquarie Group Limited and Macquarie Investment Management Global Limited is 50 Martin Place Sydney, New South Wales, Australia. The principal business address of Macquarie Management Holdings Inc. and Macquarie Investment Management Business Trust is 2005 Market Street, Philadelphia, PA 19103. The principal business address of Ivy Investment Management Company is 6300 Lamar Ave Overland Park, KS 66202.

 

  (c)

Citizenship

Macquarie Group Limited and Macquarie Investment Management Global Limited - Sydney, New South Wales, Australia Corporation Macquarie Management Holdings Inc., Ivy Investment Management Company and Macquarie Investment Management Business Trust – incorporated or formed under the laws of the State of Delaware.

 

  (d)

Title of Class of Securities

Common Stock

 

  (e)

CUSIP Number

695127100

 

Item 3.

If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

 

  (a)    ☐    Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
  (b)    ☐    Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
  (c)    ☐    Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
  (d)    ☐    Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
  (e)    ☒    An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
  (f)    ☐    An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
  (g)    ☒    A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
  (h)    ☐    A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
  (i)    ☐    A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
  (j)    ☐    A non-U.S. institution in accordance with § 240.13d–1(b)(1)(ii)(J);
  (k)    ☐    Group, in accordance with § 240.13d–1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with § 240.13d–1(b)(1)(ii)(J), please specify the type of institution:                     

 

Page 8 of 14

Item 4.

Ownership

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

 

  (a)

Amount beneficially owned:

See responses on the cover page hereto.

 

  (b)

Percent of class:

See responses on the cover page hereto.

 

  (c)

Number of shares as to which the person has:

 

  (i)

Sole power to vote or to direct the vote

   See responses on the cover page hereto.

 

  (ii)

Shared power to vote or to direct the vote

   0

 

  (iii)

Sole power to dispose or to direct the disposition of

   See responses on the cover page hereto.

 

  (iv)

Shared power to dispose or to direct the disposition of

   0

 

Item 5.

Ownership of Five Percent or Less of a Class

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following

 

Item 6.

Ownership of More than Five Percent on Behalf of Another Person

Delaware Smid Cap Growth Fund, a series of Delaware Group Equity Funds IV, a company registered under the Investment Company Act of 1940, has an interest in more than 5% of the class of securities reported herein.

 

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person

See Exhibit A.

 

Item 8.

Identification and Classification of Members of the Group

Not applicable.

 

Item 9.

Notice of Dissolution of Group

Not applicable.

 

Page 9 of 14

Item 10.

Certification

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

Signature

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

Macquarie Group Limited     

February 11, 2022

     Date

/s/ Paul Peduto

     

/s/ Charles Glorioso

Signature      Signature

 

     

 

Paul Peduto

Attorney-in-Fact

  

      

   

Charles Glorioso

Division Director

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Macquarie Management Holdings, Inc.     

February 11, 2022

     Date

/s/ Brian L. Murray

     
Signature     

 

            

Brian L. Murray

Chief Compliance Officer

     
Macquarie Investment Management Business Trust     

February 11, 2022

     Date

/s/ Brian L. Murray

     
Signature     

 

     

Brian L. Murray

Chief Compliance Officer

     

 

Page 10 of 14

EXHIBIT A

AGREEMENT TO FILE JOINT ACQUISITION STATEMENTS

AGREEMENT made this 2nd day of FEBRUARY, 2021 by and between Delaware Funds® by Macquarie listed on Annex A hereto, Macquarie Investment Management Business Trust, Macquarie Management Holdings, Inc, and the Macquarie Parties listed on Annex B hereto (collectively referred to as the “parties”).

WHEREAS, the parties hereto may be deemed to be the direct or indirect beneficial owners of the same equity securities for the purpose of the reporting requirements of Section 13(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and

WHEREAS, the regulations promulgated under Section 13(d) of the Exchange Act permit the joining of such beneficial owners in the filing of a single Joint Acquisition Statement reporting such ownership to the Securities and Exchange Commission.

NOW, THEREFORE, in consideration of the mutual covenants herein contained, and each of the parties hereto intending to be legally bound, it is agreed as follows:

1.    In the event that any two or more parties shall be deemed to be the direct or indirect beneficial owners of the same equity security required to be reported to the Securities and Exchange Commission such parties may join together in the filing of a Joint Acquisition Statement with respect to that security. Additional persons who may after the date hereof be deemed to be the direct or indirect beneficial owners of the same equity security as a party hereto and required to be reported to the Securities and Exchange Commission (a “New Party”) may be added as a party this agreement by signing a counterpart hereof. An amendment to this agreement is deemed effective upon the signature of such new party and the amendment of the applicable Annex which may be affixed to this agreement as amended. Each party hereto agrees that this agreement, as it may be amended from time to time as provided herein, is a valid and binding agreement of each such party.

2.    With respect to each Joint Acquisition Statement in which a party joins, each party acknowledges that (a) it will be eligible under applicable regulations of the Securities and Exchange Commission to join in the filing and (b) it will be responsible for the timely filing of such statement and any amendments thereto and the completeness and accuracy of the information concerning such party; but each such party shall not be responsible for the completeness and accuracy of the information concerning the other parties making the filing, unless such party knows or has reason to believe that such information with respect to such other parties is inaccurate.

3.    The parties consent to the inclusion of a copy of this agreement as an exhibit to any Joint Acquisition Statement filed on behalf of any of them.

 

Page 11 of 14

IN WITNESS WHEREOF, the parties hereto have executed this agreement by their duly authorized officers as of the date set forth above.

DELAWARE FUNDS® BY MACQUARIE (listed on Annex A hereto)

ATTEST BY:

 

/s/ Brian L. Murray

            

/s/ David Connor

Signature      Signature

 

     

 

Brian L. Murray

Chief Compliance Officer

     

David Connor

General Counsel

MACQUARIE INVESTMENT MANAGEMENT BUSINESS TRUST

/s/ Brian L. Murray

     

/s/ David Connor

Signature      Signature

 

     

 

Brian L. Murray

Chief Compliance Officer

     

David Connor

General Counsel

MACQUARIE MANAGEMENT HOLDINGS, INC.

/s/ Brian L. Murray

     

/s/ David Connor

Signature      Signature

 

     

 

Brian L. Murray

Chief Compliance Officer

     

David Connor

General Counsel

THE MACQUARIE PARTIES (LISTED ON ANNEX B HERETO)

ATTEST BY:

/s/ Paul Peduto

     

/s/ Charles Glorioso

Signature      Signature

 

     

 

Paul Peduto

Associate Director

     

Charles Glorioso

Division Director

 

Page 12 of 14

Annex A — Delaware FundsSM by Macquarie

DELAWARE GROUP EQUITY FUNDS I

DELAWARE GROUP EQUITY FUNDS II

DELAWARE GROUP EQUITY FUNDS IV

DELAWARE GROUP EQUITY FUNDS V

DELAWARE GROUP INCOME FUNDS

DELAWARE GROUP LIMITED-TERM GOVERNMENT FUNDS

DELAWARE GROUP CASH RESERVE

DELAWARE GROUP GOVERNMENT FUND

DELAWARE GROUP STATE TAX-FREE INCOME TRUST

DELAWARE GROUP TAX-FREE FUND

DELAWARE GROUP GLOBAL & INTERNATIONAL FUNDS

DELAWARE GROUP ADVISER FUNDS

DELAWARE VIP TRUST

DELAWARE POOLED TRUST

DELAWARE GROUP FOUNDATION FUNDS

DELAWARE INVESTMENTS DIVIDEND AND INCOME FUND, INC.

DELAWARE ENHANCED GLOBAL DIVIDEND AND INCOME FUND

INVESTED PORTFOLIOS

IVY HIGH INCOME OPPORTUNITIES FUND

IVY FUNDS

IVY VARIABLE INSURANCE PORTFOLIOSSM

VOYAGEUR INSURED FUNDS

VOYAGEUR INTERMEDIATE TAX FREE FUNDS

VOYAGEUR MUTUAL FUNDS

VOYAGEUR MUTUAL FUNDS II

VOYAGEUR MUTUAL FUNDS III

VOYAGEUR TAX FREE FUNDS

DELAWARE INVESTMENTS COLORADO MUNICIPAL INCOME FUND, INC.

DELAWARE INVESTMENTS NATIONAL MUNICIPAL INCOME FUND

DELAWARE INVESTMENTS MINNESOTA MUNICIPAL INCOME FUND II, INC.

 

Page 13 of 14

Annex B — the Macquarie Parties

Macquarie Group Limited

Macquarie Bank Limited

Macquarie Affiliated Managers (USA) Inc.

Macquarie Affiliated Managers Holdings (USA) Inc.

Macquarie Americas Holdings Pty Ltd.

Macquarie B.H. Pty Limited

Macquarie FG Holdings Inc.

Macquarie Funding Holdings LLC

Macquarie Investment Management Europe Limited

EXHIBIT B

Powers of Attorney for Macquarie Group Limited and Macquarie Bank Limited incorporated by reference to 13G filings made by Macquarie Group Limited and Macquarie Bank Limited on May 25, 2021.

 

Page 14 of 14

Get the next $PCRX alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$PCRX

DatePrice TargetRatingAnalyst
1/30/2025$8.00 → $25.00Sell → Hold
Truist
8/13/2024$30.00 → $8.00Buy → Sell
Truist
8/12/2024$42.00 → $11.00Overweight → Neutral
Piper Sandler
8/12/2024$45.00 → $10.00Overweight → Underweight
JP Morgan
8/12/2024Outperform → Mkt Perform
Raymond James
8/12/2024$37.00 → $14.00Outperform → Sector Perform
RBC Capital Mkts
7/3/2024$38.00 → $25.00Overweight → Equal Weight
Barclays
3/7/2024$80.00 → $45.00Overweight
JP Morgan
More analyst ratings

$PCRX
 Press Releases

Fastest customizable press release news feed in the world

See more

  • Pacira BioSciences Confirms Receipt of Director Nominations from DOMA Perpetual

    -- No Shareholder Action Required at This Time -- PARSIPPANY, N.J., March 14, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today confirmed that DOMA Perpetual Capital Management LLC ("DOMA") has nominated three candidates to stand for election to the Pacira Board of Directors (the "Board") at the Company's 2025 Annual Meeting of Stockholders. Pacira issued the following statement in response to DOMA's director nominations: "Pacira's Board and management team are taking decisive action to enhance shareholder value. We recently completed a comprehe

    $PCRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

  • DOMA Perpetual Nominates Three Highly Qualified Candidates for the Board of Pacira BioSciences

    Pacira's Stock is Down 76% Over the Last Decade, While the Board and Management Have Enriched Themselves at a Cost of Half a Billion Dollars, Roughly 50% of the Current Market Cap Under CEO and Board Member Frank Lee, the Stock Price Has Declined 33%; He is Pushing for Higher Compensation Packages for Management While Burdening Shareholders with New Risks; DOMA Believes His Views on Capital Allocation Are Misaligned With Shareholder Interest and He Has No Track Record of Creating Shareholder Value Change to the Board's Composition is Critical to Accelerate Shareholder Return and to Correct a Decade of Corporate Abuse and Lack of Stock Price Returns DOMA's Three Highly Qualified Nominees Pos

    $PCRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

  • Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    PARSIPPANY, N.J., March 06, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies, today announced the granting of inducement awards on March 4, 2025 to six new employees under Pacira's Amended and Restated 2014 Inducement Plan (the "Inducement Plan") as a material inducement to each employee's entry into employment with the company. In accordance with Nasdaq Listing Rule 5635(c)(4), the awards were approved by the Compensation Committee of the Board of Directors (the "Committee") without stockholder approval. Five employees received stock options to purchase an aggregate of 23,500 shares of Pacira c

    $PCRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

$PCRX
 Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$PCRX
 Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$PCRX
 Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$PCRX
 SEC Filings

See more

$PCRX
 Leadership Updates

Live Leadership Updates

See more

  • Pacira Announces Updates to Board of Directors

    -- Accomplished Business and Financial Leader, Laura Brege, Appointed Chair -- -- Paul J. Hastings and Andreas Wicki, PhD Retire from Board of Directors -- PARSIPPANY, N.J., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that Laura Brege has been appointed Chair of the Board. Former Chair Paul J. Hastings and Andreas Wicki, PhD. have retired from the Board. These changes align with Pacira's ongoing commitment to Board refreshment. With these changes, the Board is composed of nine directors, eight of whom are independent and

    $PCRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

  • VectorY Strengthens Leadership Team with Appointment of Jim Scibetta as New CEO

    Former CEO, Sander van Deventer to become President of R&D Lead program VTx-002 for Amyotrophic Lateral Sclerosis (ALS) advances into IND-enabling studies following favorable FDA feedback of pre-clinical package Expansion of corporate footprint into the US (Boston) VectorY Therapeutics, a biotech company developing innovative vectorized antibody therapies for the treatment of neurodegenerative diseases, announces the appointment of Jim Scibetta as Chief Executive Officer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241216441837/en/VectorY strengthens Leadership Team with appointment of Jim Scibetta as new CEO (Photo

    $PCRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

  • enGene Announces the Election of Paul Hastings and Wouter Joustra to its Board of Directors

    enGene Holdings Inc. (NASDAQ:ENGN), a clinical-stage genetic medicines company whose non-viral lead program EG-70 is in a pivotal study for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), today announced the election of Paul Hastings and Wouter Joustra as new members of its Board of Directors at the Company's 2024 annual meeting of shareholders. Shareholders also reelected incumbent director Lota Zoth. Each will serve a three-year term expiring at the 2027 annual meeting of shareholders. enGene's Board is now comprised of seven members including Richard Glickman (Chairman), Gerald Brunk, Jasper Bos, and Jason Hanson. "We are pleased to welcome Paul and Wouter to our Board of

    $ENGN
    $NAMS
    $NKTX
    $PCRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

$PCRX
 Financials

Live finance-specific insights

See more

  • Pacira BioSciences Reports Fourth Quarter and Full-Year 2024 Financial Results

    — Record revenues of $701 million in 2024 — — Full-year GAAP net loss of $100 million and adjusted EBITDA of $224 million — — Conference call today at 4:30 p.m. ET — PARSIPPANY, N.J., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today reported financial results for the fourth quarter and full-year of 2024. "Pacira enters 2025 with a sharp focus on executing our 5x30 strategy to accelerate our transition into an innovative biopharmaceutical organization and therapeutic area leader in musculoskeletal pain and adjacencies," said Frank D. L

    $PCRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

  • Pacira BioSciences Acquires Remaining Equity Stake of GQ Bio

    -- Advances Pacira's "5x30" path to becoming an innovative biopharmaceutical organization -- -- Adds novel, high-capacity, local-delivery platform for the development of genetic medicines with disease-modifying potential for prevalent musculoskeletal diseases with significant unmet needs -- -- Brings preclinical portfolio and research and development talent -- -- Provides expected near-term and long-term financial benefits with elimination of future milestone payments -- PARSIPPANY, N.J., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, tod

    $PCRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

  • Pacira to Report 2024 Financial Results on Thursday February 27, 2025

    PARSIPPANY, N.J., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it will report its fourth quarter and year ended December 31, 2024 financial results after the close of the U.S. markets on Thursday February 27, 2025. Following the release, the company will host a live conference call and webcast at 4:30 p.m. ET. For listeners who wish to participate in the question and answer session via telephone, please pre-register here. All registrants will receive dial-in information and a PIN allowing them to access the live call.

    $PCRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

$PCRX
 Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more